Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders: Bill Morice, M.D., Ph.D.
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Revolutionary Technology Advances Diagnosis of Neurodegenerative Disorders: Bill Morice, M.D., Ph.D.
-
Narrated by:
-
By:
About this listen
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered:
- Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.
- Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.
- Information physicians receive from the test, and when they should consider ordering it for their patients.
- Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet